Ot­su­ka’s fixed-dose com­bo dis­ap­points in PhI­II tri­al for Alzheimer’s ag­i­ta­tion

Ot­su­ka has run in­to a set­back bring­ing a sec­ond treat­ment for ag­i­ta­tion as­so­ci­at­ed with Alzheimer’s de­men­tia to mar­ket, as its can­di­date flunked a Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER